Gland Pharma’s record carries three areas that demand attention: a goodwill balance tied to a loss-making European acquisition now faces steeper impairment-test assumptions, receivables days have climbed past 100 while revenue recognition remains a standing audit focus, and a sharp rise in executive pay sits alongside repeated director clearances failing. The securities-regulator record is clean, and operating cash flow covered reported profit in FY26.
Key findings
- Goodwill from the Cenexi acquisition faces a narrower headroom after adverse assumption moves
Major- Goodwill of ₹2,938.70 million relates entirely to the Phixen SAS CGU acquired in April 2023, a unit that has reported negative EBITDA. The pre-tax discount rate used in the impairment test rose from 10.3% in FY24 to 10.6% in FY25 and to 12.6% in FY26, while the terminal growth assumption was cut from 2.5% to 2.0%. No impairment loss has been recorded in any year, and the company states that reasonable sensitivities are unlikely to cause the carrying amount to exceed recoverable amount as of 31 March 2026. - Revenue recognition is a standing Key Audit Matter, while receivables days have climbed to 107
Major- The auditor has flagged revenue from sale of goods as a Key Audit Matter, an area requiring the most judgement, in every annual report from FY2021 through FY2026. Standalone trade receivables grew 127% over five years to 1,520.69 crore, and receivable days reached 107 in FY26. One customer now represents 20.15% of standalone trade receivables, up from two customers at 28.50% a year earlier. - The group structure expanded rapidly through a loss-making European acquisition, creating offshore entities with negative net worth
Minor- The April 2023 acquisition of Phixen SAS brought 13 entities into the group, several with negative net worth, and Cenexi SAS reported a loss after tax of 192.1 crore in FY24. Three entities merged into Phixen SAS effective January 2025, simplifying the structure to three subsidiaries and four step-down subsidiaries as of 31 March 2026. - Disputed tax demands escalated across multiple authorities
Minor- New disputed demands include a customs order confirming an IGST demand of ₹3.53 crore plus a penalty of ₹3.53 crore, and a GST order of ₹6.29 crore, all contested in appeals. A Belgian subsidiary is in a dispute with a partner regarding alleged breaches of cooperation agreements, with financial impact that cannot be reliably estimated. - Deloitte replaced S.R. Batliboi as statutory auditor in FY24
Minor- S.R. Batliboi & Associates LLP served from at least FY21 through FY23, and Deloitte Haskins & Sells was appointed for five years from the conclusion of the 45th AGM on August 31, 2023. No auditor resignations occurred during FY22, FY23, FY24, or FY25, and the subsidiary auditor change in Singapore was a single event with no disclosed concern. - The securities-regulator record is clean since listing, and drug-regulator observations remain procedural
Clean- No penalties or strictures were imposed by SEBI or stock exchanges in any year from FY21 through FY26, except fines of ₹15,000 levied by each of the stock exchanges (NSE and BSE) in FY22. The US FDA issued a Form 483 with three observations at the JNPC facility in February 2025, and ANSM France issued 11 observations at the Cenexi Fontenay facility in June 2025, with no disruption to operations.
What to watch
- USFDA Form 483 observations. Three observations for the JNPC Visakhapatnam facility, issued 25 February 2025.
- ANSM observations. Eleven observations for the Cenexi Fontenay facility, reported 03 June 2025.
- Goodwill impairment test. Next annual test for the Phixen SAS CGU as of 31 March 2027, following the discount-rate increase from 10.6% to 12.6% and terminal-growth cut from 2.5% to 2.0% in FY26.
- Belgian subsidiary dispute. The outcome of the Cenexi Laboratories Thissen SA mediation remains pending, with no reliable estimate of financial impact as of the FY25 Annual Report.
- CEO appointment. A new CEO is being sought following Mr. Shyamakant Giri’s resignation on 30 April 2026.
Bottom line: This is a disclosed and audited record with a clean securities-regulator history and a CFO/PAT ratio that declined to 1.00x in FY26 from 1.29x-1.31x in the prior two years. The risk concentrates in three places: the Cenexi goodwill, where impairment assumptions have moved adversely against a unit still reporting negative EBITDA; the receivables book, where concentration is rising and collection days are lengthening; and the governance signals from repeated director clearances failing and a pay-and-ESOP structure that drew institutional dissent. Watch the goodwill test, the receivables line, and the CEO appointment.